Table 3.
Variables | UVA | MVA | ||
---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | |
Tumor stage | ||||
T1 | Reference | 0.022 | Reference | 0.648 |
T2 | 3.72 (1.01–13.71) | 0.048 | 1.29 (0.29–5.63) | 0.739 |
T3 | 1.23 (0.31–4.93) | 0.774 | 0.84 (0.16–4.37) | 0.839 |
T4 | 53.15 (2.77–1020.21) | 0.008 | 5.44 (0.21–142.99) | 0.310 |
HPV/p16 status | 0.24 (0.08–0.76) | 0.015 | 0.18 (0.039–0.80) | 0.024 |
LVI | 0.36 (0.12–1.13) | 0.080 | 0.39 (0.10–1.60) | 0.192 |
Extent of surgery | 2.55 (0.92–7.04) | 0.072 | 1.58 (0.46–5.41) | 0.463 |
Adjuvant CRT | 0.24 (0.08–0.71) | 0.010 | 0.19 (0.05–0.70) | 0.012 |
Bold indicates statistical significance p values (< 0.05)
LVI Lymphovascular invasion, CRT Chemoradiotherapy, UVA Cox Univariate analysis, MVA Cox Multivariate analysis, HR Hazard ratio